[Innovation-driven pharmaceutical development and clinical advancement]

With a focus on strengthening innovative drug development and promoting the clinical application of emerging medical technologies, we have summarized innovation-driven pharmaceutical development and clinical advancement, highlighting the key challenges, current hotspots, and potential breakthroughs, while outlining priority directions for fostering deeper integration between pharmaceutical development and medical practice. This paper provides a systematic analysis of the progress, challenges, and future directions of China's innovative drug development. Currently, through biomedical technology innovation, comprehensive policy support, accelerated regulatory reviews and approval processes, and reforms in the payment system, China has risen to a leading global position in terms of the number of innovative drugs developed and license-out deals. However, challenges remain, including weak capacity for original innovation, insufficient alignment with clinical needs, and limited international engagement. To address these, the country has recently launched the national major science and technology special project on drug development in the new phase. This initiative aims to shift the focus toward capacity building, drug discovery and original innovation, while optimizing the project organization and management to foster a collaborative innovation ecosystem. The goal is to establish an independent, controllable, and world-leading drug innovation system by 2035, thereby providing strong support for the "Healthy China" initiative.